<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297319</url>
  </required_header>
  <id_info>
    <org_study_id>5076</org_study_id>
    <nct_id>NCT04297319</nct_id>
  </id_info>
  <brief_title>The Use of Laser in the Treatment of Atrophic Vulvovaginitis</brief_title>
  <official_title>The Use of Laser in the Treatment of Atrophic Vulvovaginitis and Its Consequent Improvement in Sexual Satisfaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and security of laser for atrophy treatment. Half of
      participants will receive the laser treatment and the other half placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thermal laser treatments are proposed as the newest treatments for atrophy. Through the
      thermal effect it would stimulates de mucosa, enhances the collagen component and the
      vascularization. Collagen remodeling and new collagen synthesis has been suggested as a
      mechanism of laser induced skin resurfacing and remodeling of vaginal connective tissue.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, randomized, control clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The patient and the outcomes assessor and principal investigator has not access to the randomization system</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Female Sexual Function Index questionnaire</measure>
    <time_frame>baseline, and week 4 after treatment</time_frame>
    <description>Female Sexual Function Index is a self- administered questionnaire that evaluate 19 items about sexual life. Minimum score is 2, and the highest is 36. Higher score mean a better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Female Sexual Function Index questionnaire</measure>
    <time_frame>baseline,and week 12 after treatment</time_frame>
    <description>Female Sexual Function Index is a self- administered questionnaire that evaluate 19 items about sexual life. Minimum score is 2, and the highest is 36. Higher score mean a better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Female Sexual Function Index questionnaire</measure>
    <time_frame>baseline, and week 36 after treatment</time_frame>
    <description>Female Sexual Function Index is a self- administered questionnaire that evaluate 19 items about sexual life. Minimum score is 2, and the highest is 36. Higher score mean a better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Cytology Improvement</measure>
    <time_frame>baseline, and week 4 after treatment</time_frame>
    <description>Vagina cytology will be obtain to evaluate initial conditions of the vagina and modifications after treatment. Papanicolaou coloration and the count of superficial, intermediate, parabasal and basal cells will be applied to measure improvement of vaginal atrophy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Cytology Improvement</measure>
    <time_frame>baseline, and week 12 after treatment</time_frame>
    <description>Vagina cytology will be obtain to evaluate initial conditions of the vagina and modifications after treatment. Papanicolaou coloration and the count of superficial, intermediate, parabasal and basal cells will be applied to measure improvement of vaginal atrophy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Cytology Improvement</measure>
    <time_frame>baseline, and week 36 after treatment</time_frame>
    <description>Vagina cytology will be obtain to evaluate initial conditions of the vagina and modifications after treatment. Papanicolaou coloration and the count of superficial, intermediate, parabasal and basal cells will be applied to measure improvement of vaginal atrophy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vaginal acidity measure</measure>
    <time_frame>baseline, and week 4 after treatment</time_frame>
    <description>the normal vaginal acidity is between 3,8 a 4,5. In postmenopausal women is higher. We are going to evaluate the improvement in vaginal acidity to normal values of premenopausal women. It will be evaluate with specific acidity measurement strips (this strips measures between 3.8 y 5.4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vaginal acidity measure</measure>
    <time_frame>baseline, and week 12 after treatment</time_frame>
    <description>the normal vaginal acidity is between 3,8 a 4,5. In postmenopausal women is higher. We are going to evaluate the improvement in vaginal acidity to normal values of premenopausal women. It will be evaluate with specific acidity measurement strips (this strips measures between 3.8 y 5.4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vaginal pH measure</measure>
    <time_frame>baseline,and week 36 after treatment</time_frame>
    <description>the normal vaginal ph is between 3,8 a 4,5. In postmenopausal women is higher. We are going to evaluate the improvement in vaginal acidity to normal values of premenopausal women. It will be evaluate with specific acidity measurement strips (this strips measures between 3.8 y 5.4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patient with Local Estrogen therapy requirement post intervention</measure>
    <time_frame>baseline,and week 48</time_frame>
    <description>Number of patients that Need estrogen replacement for atrophy vulvovaginal symptoms, despite the intervention.This will be evaluate with a Yes/No question.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participant with Adverse events reported in each visit</measure>
    <time_frame>Baseline,and week 48</time_frame>
    <description>It will be evaluate the number of patients that reported adverse events such as dyspareunia, irritation, edema, vaginal dryness, genital bleeding, vaginal discharge, pain, lesions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Lasers</condition>
  <condition>Atrophy of Vagina</condition>
  <condition>Atrophy Vulva</condition>
  <arm_group>
    <arm_group_label>1 - Laser intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser diiodo treatment, 3 procedures of 5-10 minutes at intervals of 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Laser placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Only the laser speculum is placed in the vagina but the laser is not activated. 3 procedures of 5-10 minutes at intervals of 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser diiodo</intervention_name>
    <description>3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.</description>
    <arm_group_label>1 - Laser intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser Placebo</intervention_name>
    <description>3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.</description>
    <arm_group_label>2 - Laser placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Menopause women with vulvovaginal symptoms of atrophy

          -  No previous estrogen treatment for the last 30 days

          -  Active sexual life (vaginal penetration)

          -  Accept to participate

          -  Pap atrophy or hypotrophy in the last year

        Exclusion Criteria:

          -  Vulvovaginal diseases

          -  Abnormal uterine bleeding

          -  Antidepressants drugs

          -  Uncontrolled diabetes

          -  Cervical intraepithelial lesions or cancer

          -  Photosensitized or under treatment with photosensibilized drugs

          -  Collagen diseases

          -  Vulvovaginal infections in the last 15 days

          -  Immunosuppressed patients or under immunosuppressed treatments
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>claudia E Marchitelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano de Buenos Aires-Argentina.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia E Marchitelli, MD</last_name>
    <phone>00541149590200</phone>
    <phone_ext>8440</phone_ext>
    <email>claudia.marchitelli@hospitalitaliano.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariela Prada, MD</last_name>
    <phone>00541149590200</phone>
    <phone_ext>8440</phone_ext>
    <email>mariela.prada@hospitalitaliano.org.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <zip>1199</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia E marchitelli, MD</last_name>
      <phone>541149590200</phone>
      <phone_ext>8440</phone_ext>
      <email>claudia.marchitelli@hospitalitaliano.org.ar</email>
    </contact>
    <contact_backup>
      <last_name>Mariela Prada, MD</last_name>
      <phone>54119590200</phone>
      <phone_ext>8440</phone_ext>
      <email>mariela.prada@hiba.org.ar</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Knight C, Logan V, Fenlon D. A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors. Ecancermedicalscience. 2019 Dec 12;13:988. doi: 10.3332/ecancer.2019.988. eCollection 2019.</citation>
    <PMID>32010212</PMID>
  </reference>
  <results_reference>
    <citation>Adabi K, Golshahi F, Niroomansh S, Razzaghi Z, Ghaemi M. Effect of the Fractional CO(2) Laser on the Quality of Life, General Health, and Genitourinary Symptoms in Postmenopausal Women With Vaginal Atrophy: A Prospective Cohort. J Lasers Med Sci. 2020 Winter;11(1):65-69. doi: 10.15171/jlms.2020.11. Epub 2020 Jan 18.</citation>
    <PMID>32099629</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>CLAUDIA ESTER MARCHITELLI</investigator_full_name>
    <investigator_title>Chief of the Gynecology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvovaginitis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

